Molecular Partners AG (MOLN)

Compare

3.8400

-0.2300

(-5.65%)

At close: April 1 at 4:00:00 PM EDT

3.8950

+0.06

+(1.43%)

After hours: April 1 at 4:05:09 PM EDT

Molecular Partners to hold three poster presentations at AACR 2025

Update on IND-enabling data for MP0712, a Radio-DARPin targeting DLL3 and labeled with 212Pb, co-developed with Orano Med; entering FIH studies in 2025 for the treatment of small cell lung cancer First preclinical data on second 212Pb-based Radio-DARPin co-developed with Orano Med, targeting the membrane-proximal region of mesothelin (MSLN) in solid tumors Additional preclinical proof-of-concept data on CD3 Switch-DARPin T cell engager with CD2 co-stimulation in solid tumors ZURICH-SCHLIEREN, Sw

GlobeNewswire 7 days ago

MLLCF

MOLN
-5.65%
Molecular Partners Publishes Invitation to Annual General Meeting 2025

ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., March 25, 2025 (GLOBE NEWSWIRE) -- Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin therapeutics, today published the invitation to the Annual General Meeting 2025. The Annual General Meeting will be held on Wednesday, April 16, 2025, 9.00 CET (doors open at 8.30 CET), at JED Events, Zürcherstrasse 39, 8952 Schlieren, Switzerland. Invitation to

GlobeNewswire 7 days ago

MLLCF

MOLN
-5.65%
Molecular Partners AG (MLLCF) (FY 2024) Earnings Call Highlights: Strategic Shifts and ...

Despite challenges with collaborations, Molecular Partners AG (MLLCF) maintains a strong cash position and advances its promising pipeline.

GuruFocus.com 24 days ago

MOLN.SW

NVS
Molecular Partners Reports Highlights from Q4 2024 and Key Financials for Full Year 2024

DLL3 targeting Radio-DARPin MP0712 to enter first-in-human study in 2025, pending regulatory clearanceStrategic partnership with Orano Med on Radio-DARPins now expanded to ten programsMP0533 Phase 1/2a clinical data show improved response rate and depth in ongoing cohort, additional dosing optimization planned; data expected throughout 2025Strong financial position with CHF 149 million in cash, cash equivalents and short-term deposits at end of 2024, expected to support operations well into 2027

GlobeNewswire 26 days ago

MLLCF

MOLN
-5.65%
Molecular Partners Announces Participation at Upcoming Investor Conferences and 2024 Financial Results Conference Call

Participation in fireside chats at TD Cowen and Leerink healthcare conferencesCall on 2024 financial results on March 7 at 2.00 pm CET (8.00 am ET) ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., Feb. 28, 2025 (GLOBE NEWSWIRE) -- Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin therapeutics (“Molecular Partners” or the “Company”), today announced its attendance and presentations at upcoming in

GlobeNewswire last month

MLLCF

MOLN
-5.65%
Molecular Partners Outlines Clinical Expansion Plans and Strengthens Radiopharma Strategic Focus for 2025 at 43rd Annual J.P. Morgan Healthcare Conference

Radio-DARPin MP0712 against DLL3, in co-development with Orano Med, to enter first-in-human study in 2025Mesothelin named as second target in Radio-DARPin pipeline, program to be co-developed with Orano MedOrano Med partnership on Radio-DARPins now expanded to 10 programsMP0533 clinical data show improved response rate and depth in cohort 8 with steeper step-up and more frequent dosing; additional dose densification planned in cohort 9, updates expected in 2025CD3 Switch-DARPin research proof-of

GlobeNewswire 2 months ago

MLLCF

MOLN
-5.65%
Molecular Partners and Orano Med expand partnership to develop Targeted Alpha Radio-Therapies for cancer

New agreement enables both companies to fuel a broad and innovative pipeline of 212Pb-Radio-DARPin candidates, bringing the total number of programs up to tenExpanded partnership highlights the parties’ emerging leadership in targeted alpha therapies (TAT), leveraging Orano Med’s expertise in the development of 212Pb-based TAT and vast proprietary supply of 212Pb and Molecular Partners’ unique Radio-DARPins as an ideal vector for radiopharmaceuticalsMost advanced 212Pb-Radio-DARPin, DLL3-targete

GlobeNewswire 2 months ago

MLLCF

MOLN
-5.65%
Molecular Partners to Present at JP Morgan Healthcare Conference and Baader Helvea Swiss Equities Conference in January

ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., Dec. 17, 2024 (GLOBE NEWSWIRE) -- Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin therapeutics (“Molecular Partners” or the “Company”), today announced it will attend and present the Company’s latest developments and outlook for 2025 at two upcoming investor conferences in January. Baader Helvea Swiss Equities Conference, taking place January 8-

GlobeNewswire 3 months ago

MLLCF

MOLN
-5.65%
Wall Street Analysts Think Molecular Partners AG Sponsored ADR (MOLN) Could Surge 80.72%: Read This Before Placing a Bet

The consensus price target hints at an 80.7% upside potential for Molecular Partners AG Sponsored ADR (MOLN). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Zacks 3 months ago

MOLN.SW
Molecular Partners Presents Clinical Data Supporting its Ongoing MP0533 Study and Preclinical Data on Next-Gen Conditioning Agent MP0621 at ASH 2024

MP0533 phase 1/2a dose escalation study continues with overall acceptable safety profile to date as well as initial antileukemic and pharmacodynamic activity Clinical protocol amendment in process with optimized dosing scheme to overcome target-mediated drug disposition and test the full potential of MP0533 Switch-DARPin MP0621 demonstrates intended mechanism in vivo, achieving killing of cKit+ cells while reducing off-target effects seen with systemic anti-CD47 blockade ZURICH-SCHLIEREN, Switze

GlobeNewswire 3 months ago

MLLCF

MOLN
-5.65%
Molecular Partners Presents Preclinical Proof-of-Concept for CD3 Switch-DARPin T Cell Engager, Clinical Biomarker Analyses for MP0317 at SITC 2024

Preclinical proof-of-concept data supports the potential of CD3 Switch-DARPin platform to activate and boost T cells in the presence of tumor targets only MP0317’s ability to activate CD40 in a variety of tumor types further evidenced by comprehensive clinical biomarker analyses ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs k

GlobeNewswire 4 months ago

MLLCF

MOLN
-5.65%
Molecular Partners Announces Upcoming Poster Presentations at the 65th ASH Annual Meeting and Exposition

Clinical update from ongoing MP0533 phase 1/2a dose escalation study confirms overall acceptable safety profile observed so far and initial antileukemic and pharmacodynamic activity Switch-DARPin MP0621 demonstrates cKit+ cell killing while reducing off-target effects seen with systemic anti-CD47 blockade ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., Nov. 05, 2024 (GLOBE NEWSWIRE) -- Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of c

GlobeNewswire 4 months ago

MLLCF

MOLN
-5.65%
Molecular Partners Q3 2024 Interim Management Statement: Multiple Updates Across Portfolio, Radio-DARPin candidate MP0712 preparing for clinical entry, MP0533 Phase 1 on-going

Radio-DARPin Therapy (RDT) Candidate MP0712 supported by in vivo data presented at the European Association of Nuclear Medicine (EANM) Congress; first-in-human start and initial clinical data expected in 2025 RDT strategic agreement with Orano Med revised and strengthened: both companies to co-develop four 212Pb-based RDT candidates, including MP0712 MP0533 phase 1 dose escalation study continues; update to be presented at the American Society for Hematology Annual Meeting (ASH); protocol being

GlobeNewswire 4 months ago

MLLCF

MOLN
-5.65%
Molecular Partners Announces Pricing of $20 Million Underwritten Offering

ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., Oct. 25, 2024 (GLOBE NEWSWIRE) -- Ad hoc announcement pursuant to Art. 53 LR – Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin therapeutics (“Molecular Partners” or the “Company”), today announced the pricing of an underwritten offering in the United States of 3,642,988 American Depositary Shares (“ADSs”) representing 3,642,988 ordinary shares a

GlobeNewswire 5 months ago

MLLCF

MOLN
-5.65%
Molecular Partners Expands Radio-DARPin Collaboration

Molecular Partners (MOLN) has released an update. Molecular Partners and Orano Med have expanded their co-development agreement to create four Radio-DARPin programs, with each company securing commercialization rights to two. The strengthened collaboration aims at advancing targeted cancer therapies, with first-in-human studies expected to begin in 2025. Despite the expansion, Molecular Partners anticipates no immediate financial impact for 2024 and maintains a strong cash position. For further

TipRanks 5 months ago

MLLCF

MOLN
-5.65%
Molecular Partners and Orano Med Present Additional Positive Preclinical Data Supporting DLL3 Targeting Radio-DARPin Therapeutic Candidate MP0712 at EANM 2024

Dose-dependent efficacy observed with favorable safety profile Attractive tumor to kidney ratios shown in biodistribution studies Picomolar affinity and high specificity for DLL3 as precision attributes for alpha radiation therapy Molecular Partners and Orano Med preparing for clinical entry in 2025 ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass. and PARIS, Oct. 22, 2024 (GLOBE NEWSWIRE) -- Ad hoc announcement pursuant to Art. 53 LR – Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-

GlobeNewswire 5 months ago

MLLCF

MOLN
-5.65%
Molecular Partners and Orano Med Strengthen Agreement to Co-Develop 212Pb-Based Radio-DARPin Therapeutics

Under the revised agreement, both companies will co-develop four Radio-DARPin programs; each company will have the right to commercialize two programs (previously one each)Molecular Partners will hold commercial rights to the second nominated Radio-DARPin Candidate, in addition to rights to first program MP0712 targeting DLL3 ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., Oct. 22, 2024 (GLOBE NEWSWIRE) -- Ad hoc announcement pursuant to Art. 53 LR – Molecular Partners AG (SIX: MOLN; NASDAQ: M

GlobeNewswire 5 months ago

MLLCF

MOLN
-5.65%
Molecular Partners Announces upcoming poster presentations at the 2024 SITC Annual Meeting

Preclinical proof-of-concept data supports CD3 Switch-DARPin platform for T cell engagers with enhanced function in solid tumors Biomarker data on completed phase 1 study of MP0317 (FAP x CD40) shows intended and marked tumor microenvironment modulation ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., Oct. 04, 2024 (GLOBE NEWSWIRE) -- Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin therapeutic

GlobeNewswire 5 months ago

MLLCF

MOLN
-5.65%
Molecular Partners Announces Upcoming Top-Rated Oral Presentation on MP0712, a ²¹²Pb-labeled Radio-DARPin Therapeutic targeting DLL3 for Small Cell Lung Cancer co-developed with Orano Med, at EANM 2024

First RDT candidate MP0712 shows low kidney accumulation and high tumor uptake in preclinical models MP0712 treatment leads to strong tumor growth inhibition with a good safety profile in vivo ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., Sept. 27, 2024 (GLOBE NEWSWIRE) -- Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin therapeutics, today announced that the Company will present on its lead

GlobeNewswire 6 months ago

MLLCF

MOLN
-5.65%
Molecular Partners Reports H1 2024 Corporate Highlights and Financials

First Radio-DARPin Therapy (RDT) candidate MP0712 nominated; supporting preclinical package presented at SNMMI; initial clinical data expected in 2025 Strategic collaboration agreement signed with Orano Med to co-develop 212Pb-based RDT candidates for multiple oncology targets, including MP0712 MP0533 phase 1 dose escalation continues with cohort 8 open; clinical data update on amended dosing scheme expected in 2025 Switch-DARPin Platform: preclinical data supporting mechanism of action of Switc

GlobeNewswire 7 months ago

MLLCF

MOLN
-5.65%

Performance Overview

Return	MOLN	MSCI WORLD (^990100-USD-STRD)
YTD	-23.05%	-1.91%
1-Year	-8.57%	0.00%
3-Year	-81.31%	+19.48%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Molecular Partners AG (MOLN)

Molecular Partners to hold three poster presentations at AACR 2025

Molecular Partners Publishes Invitation to Annual General Meeting 2025

Molecular Partners AG (MLLCF) (FY 2024) Earnings Call Highlights: Strategic Shifts and ...

Molecular Partners Reports Highlights from Q4 2024 and Key Financials for Full Year 2024

Molecular Partners Announces Participation at Upcoming Investor Conferences and 2024 Financial Results Conference Call

Molecular Partners Outlines Clinical Expansion Plans and Strengthens Radiopharma Strategic Focus for 2025 at 43rd Annual J.P. Morgan Healthcare Conference

Molecular Partners and Orano Med expand partnership to develop Targeted Alpha Radio-Therapies for cancer

Molecular Partners to Present at JP Morgan Healthcare Conference and Baader Helvea Swiss Equities Conference in January

Wall Street Analysts Think Molecular Partners AG Sponsored ADR (MOLN) Could Surge 80.72%: Read This Before Placing a Bet

Molecular Partners Presents Clinical Data Supporting its Ongoing MP0533 Study and Preclinical Data on Next-Gen Conditioning Agent MP0621 at ASH 2024

Molecular Partners Presents Preclinical Proof-of-Concept for CD3 Switch-DARPin T Cell Engager, Clinical Biomarker Analyses for MP0317 at SITC 2024

Molecular Partners Announces Upcoming Poster Presentations at the 65th ASH Annual Meeting and Exposition

Molecular Partners Q3 2024 Interim Management Statement: Multiple Updates Across Portfolio, Radio-DARPin candidate MP0712 preparing for clinical entry, MP0533 Phase 1 on-going

Molecular Partners Announces Pricing of $20 Million Underwritten Offering

Molecular Partners Expands Radio-DARPin Collaboration

Molecular Partners and Orano Med Present Additional Positive Preclinical Data Supporting DLL3 Targeting Radio-DARPin Therapeutic Candidate MP0712 at EANM 2024

Molecular Partners and Orano Med Strengthen Agreement to Co-Develop 212Pb-Based Radio-DARPin Therapeutics

Molecular Partners Announces upcoming poster presentations at the 2024 SITC Annual Meeting

Molecular Partners Announces Upcoming Top-Rated Oral Presentation on MP0712, a ²¹²Pb-labeled Radio-DARPin Therapeutic targeting DLL3 for Small Cell Lung Cancer co-developed with Orano Med, at EANM 2024

Molecular Partners Reports H1 2024 Corporate Highlights and Financials

Performance Overview